Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells.
There is evidence that the overproduction of apoB-100-containing lipoproteins by the liver is the underlying event in some forms of dyslipoproteinemia. This metabolic status is associated to an increased risk of developing premature coronary artery disease CAD. The conclusions from previous studies suggested that the availability to the hepatocytes of cholesterol that is readily esterified is an important determinant for VLDL and LDL secretion. In the present study, we set out to investigate the effect of the specific stimulation and inhibition of the rate-limiting enzyme of the cholesterol esterification, acyl-CoA:cholesterol acyltransferase (ACAT, E.C. 2.3.1.26), on the lipid and on the apoB-100 secretion rate from a human hepatoma cell line (HepG2). When the specific ACAT inhibitor FCE 27677 (10-5 M) was added to the cultures, a decrease of the cellular cholesteryl ester content and at the same time a significant reduction of the neutral lipids and of the apoB-100 secretion rate were noticed. The stimulation of ACAT by 25-hydroxycholesterol (20 microgram/ml) caused a 4-fold increase of the cellular cholesteryl ester content and a 2-fold increase of the lipoprotein secretion rate. FCE 27677 (10-5 M to 10-7 M) prevented the effects elicited by the oxysterol. On the contrary, lovastatin (10-6 M) and gemfibrozil (10-6 M) had no effect. The analysis of the lipid and of the apolipoprotein composition of the lipoproteins secreted in the medium revealed that ACAT inhibition had the dual effect of both decreasing the number of apoB-100-containing lipoproteins secreted as well as their cholesteryl ester load. Altogether, these data support the idea of a close relationship between ACAT activation, leading to increased cholesteryl ester availability, and apoB-100-containing lipoprotein secretion. It is speculated that ACAT inhibitors may prove useful for the treatment of human dyslipoproteinemias caused by the hepatic overproduction of apoB-100-containing lipoproteins.
Musanti
R
R
Pharmacia Farmitalia Carlo Erba Research Institute, Cardiovascular Department, Milan, Italy.
Giorgini
L
L
Lovisolo
P P
PP
Pirillo
A
A
Chiari
A
A
Ghiselli
G
G
D000418:Albumins / Q000378:metabolism; D000814:Aniline Compounds / Q000494:pharmacology*; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D015248:Gemfibrozil / Q000494:pharmacology; D006801:Humans; D006888:Hydroxycholesterols / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008055:Lipids / Q000096:biosynthesis; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D008148:Lovastatin / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000494:pharmacology*; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured
D000418:Albumins; D000814:Aniline Compounds; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D004791:Enzyme Inhibitors; C099233:FCE 27677; D006888:Hydroxycholesterols; D000960:Hypolipidemic Agents; D008055:Lipids; D010671:Phenylurea Compounds; C007997:25-hydroxycholesterol; D008148:Lovastatin; D002785:Sterol O-Acyltransferase; D015248:Gemfibrozil